ZOLEDRONIC ACID HEMIPENTAHYDRATE

Details

Stereochemistry	ACHIRAL
Molecular Formula	2C5H10N2O7P2.5H2O
Molecular Weight	634.2556
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure of ZOLEDRONIC ACID HEMIPENTAHYDRATE

Structure Search

SMILES

O.O.O.O.O.OC(CN1C=CN=C1)(P(O)(O)=O)P(O)(O)=O.OC(CN2C=CN=C2)(P(O)(O)=O)P(O)(O)=O

InChI

InChIKey=AZZILOGHCMYHQY-UHFFFAOYSA-N

InChI=1S/2C5H10N2O7P2.5H2O/c2*8-5(15(9,10)11,16(12,13)14)3-7-2-1-6-4-7;;;;;/h2*1-2,4,8H,3H2,(H2,9,10,11)(H2,12,13,14);5*1H2

HIDE SMILES / InChI

Molecular Formula	H2O
Molecular Weight	18.0153
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	C5H10N2O7P2
Molecular Weight	272.0896
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/21386lbl.pdf

Zoledronic acid (Reclast, Aclasta, Zometa) is an intravenous, highly potent amino-bisphosphonate approved worldwide, including in the USA, EU and Japan for use in patients with primary or secondary osteoporosis or low bone mass (approved indications vary between countries). Its high affinity to and long half-life in bone, and long duration of action allow for once-yearly administration, which has the potential to improve adherence to therapy. Zoledronic acid once yearly for up to 3 years improved bone mineral density (BMD) at several skeletal sites, reduced fracture risk and bone turnover, and/or preserved bone structure and mass relative to placebo in clinical studies in patients with primary or secondary osteoporosis. While additional benefits were seen when treatment was continued for up to 6 years, as evidenced by a reduced risk of vertebral fractures and higher BMD relative to 3 years’ therapy, there was the minimal advantage of treatment beyond 6 years. Therefore, in patients with low fracture risk, treatment discontinuation should be considered after approximately 5 years’ therapy. Zoledronic acid administered annually or once in 2 years was also effective in preventing bone loss in patients with low bone mass. Zoledronic acid was generally well tolerated, with the most common adverse events (AEs) being transient, mild-to-moderate post-infusion symptoms, which decreased with subsequent infusions.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Farnesyl diphosphate synthase 28 Target ID: CHEMBL1782 Sources: https://www.ncbi.nlm.nih.gov/pubmed/22390415	Inhibitor 8297	4.1 nM [IC50]
Geranylgeranyl pyrophosphate synthetase 18 Target ID: CHEMBL4769 Sources: https://www.ncbi.nlm.nih.gov/pubmed/17535895	Inhibitor 8297	97.0 µM [IC50]
Carbonic anhydrase XIV 22 Target ID: CHEMBL3510 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24813742	Inhibitor 8297	92.0 nM [IC50]
Carbonic anhydrase II 88 Target ID: CHEMBL205 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24650641	Inhibitor 8297	62.0 nM [IC50]

Conditions

Condition	Modality	Highest Phase	Product
Hypercalcemia 21 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/21386lbl.pdf	Primary	Approved 8429	Zometa Approved Use INDICATIONS AND USAGE Hypercalcemia of Malignancy. Zometa® (zoledronic acid for injection) is indicated for the treatment of hypercalcemia of malignancy. Vigorous saline hydration, an integral part of hypercalcemia therapy, should be initiated promptly and an attempt should be made to restore the urine output to about 2 L/day throughout treatment. Mild or asymptomatic hypercalcemia may be treated with conservative measures (i.e., saline hydration, with or without loop diuretics). Patients should be hydrated dequately throughout the treatment, but overhydration, especially in those patients who have cardiac failure, must be avoided. Diuretic therapy should not be employed prior to correction of hypovolemia. The safety and efficacy of Zometa in the treatment of hypercalcemia associated with hyperparathyroidism or with other non-tumor-related conditions has not been established. Multiple Myeloma and Bone Metastases of Solid Tumors. Zometa is indicated for the treatment of patients with multiple myeloma and patients with documented bone metastases from solid tumors, in conjunction with standard antineoplastic therapy. Prostate cancer should have progressed after treatment with at least one hormonal therapy Launch Date 2001
Disuse osteoporosis 9 Sources: https://clinicaltrials.gov/ct2/show/NCT02042872	Primary	Approved 8429	Zometa Approved Use INDICATIONS AND USAGE Hypercalcemia of Malignancy. Zometa® (zoledronic acid for injection) is indicated for the treatment of hypercalcemia of malignancy. Vigorous saline hydration, an integral part of hypercalcemia therapy, should be initiated promptly and an attempt should be made to restore the urine output to about 2 L/day throughout treatment. Mild or asymptomatic hypercalcemia may be treated with conservative measures (i.e., saline hydration, with or without loop diuretics). Patients should be hydrated dequately throughout the treatment, but overhydration, especially in those patients who have cardiac failure, must be avoided. Diuretic therapy should not be employed prior to correction of hypovolemia. The safety and efficacy of Zometa in the treatment of hypercalcemia associated with hyperparathyroidism or with other non-tumor-related conditions has not been established. Multiple Myeloma and Bone Metastases of Solid Tumors. Zometa is indicated for the treatment of patients with multiple myeloma and patients with documented bone metastases from solid tumors, in conjunction with standard antineoplastic therapy. Prostate cancer should have progressed after treatment with at least one hormonal therapy Launch Date 2001
Prostate cancer with bone metastasis 9 Sources: https://clinicaltrials.gov/ct2/show/NCT00241111	Primary	Approved 8429	Zometa Approved Use INDICATIONS AND USAGE Hypercalcemia of Malignancy. Zometa® (zoledronic acid for injection) is indicated for the treatment of hypercalcemia of malignancy. Vigorous saline hydration, an integral part of hypercalcemia therapy, should be initiated promptly and an attempt should be made to restore the urine output to about 2 L/day throughout treatment. Mild or asymptomatic hypercalcemia may be treated with conservative measures (i.e., saline hydration, with or without loop diuretics). Patients should be hydrated dequately throughout the treatment, but overhydration, especially in those patients who have cardiac failure, must be avoided. Diuretic therapy should not be employed prior to correction of hypovolemia. The safety and efficacy of Zometa in the treatment of hypercalcemia associated with hyperparathyroidism or with other non-tumor-related conditions has not been established. Multiple Myeloma and Bone Metastases of Solid Tumors. Zometa is indicated for the treatment of patients with multiple myeloma and patients with documented bone metastases from solid tumors, in conjunction with standard antineoplastic therapy. Prostate cancer should have progressed after treatment with at least one hormonal therapy Launch Date 2001
Renal osteodystrophy 11 Sources: https://clinicaltrials.gov/ct2/show/NCT01675089	Primary	Approved 8429	Zometa Approved Use INDICATIONS AND USAGE Hypercalcemia of Malignancy. Zometa® (zoledronic acid for injection) is indicated for the treatment of hypercalcemia of malignancy. Vigorous saline hydration, an integral part of hypercalcemia therapy, should be initiated promptly and an attempt should be made to restore the urine output to about 2 L/day throughout treatment. Mild or asymptomatic hypercalcemia may be treated with conservative measures (i.e., saline hydration, with or without loop diuretics). Patients should be hydrated dequately throughout the treatment, but overhydration, especially in those patients who have cardiac failure, must be avoided. Diuretic therapy should not be employed prior to correction of hypovolemia. The safety and efficacy of Zometa in the treatment of hypercalcemia associated with hyperparathyroidism or with other non-tumor-related conditions has not been established. Multiple Myeloma and Bone Metastases of Solid Tumors. Zometa is indicated for the treatment of patients with multiple myeloma and patients with documented bone metastases from solid tumors, in conjunction with standard antineoplastic therapy. Prostate cancer should have progressed after treatment with at least one hormonal therapy Launch Date 2001
Postmenopausal osteoporosis 59 Sources: https://clinicaltrials.gov/ct2/show/NCT02499237	Primary	Approved 8429	Zometa Approved Use INDICATIONS AND USAGE Hypercalcemia of Malignancy. Zometa® (zoledronic acid for injection) is indicated for the treatment of hypercalcemia of malignancy. Vigorous saline hydration, an integral part of hypercalcemia therapy, should be initiated promptly and an attempt should be made to restore the urine output to about 2 L/day throughout treatment. Mild or asymptomatic hypercalcemia may be treated with conservative measures (i.e., saline hydration, with or without loop diuretics). Patients should be hydrated dequately throughout the treatment, but overhydration, especially in those patients who have cardiac failure, must be avoided. Diuretic therapy should not be employed prior to correction of hypovolemia. The safety and efficacy of Zometa in the treatment of hypercalcemia associated with hyperparathyroidism or with other non-tumor-related conditions has not been established. Multiple Myeloma and Bone Metastases of Solid Tumors. Zometa is indicated for the treatment of patients with multiple myeloma and patients with documented bone metastases from solid tumors, in conjunction with standard antineoplastic therapy. Prostate cancer should have progressed after treatment with at least one hormonal therapy Launch Date 2001

C_max

Value	Dose	Co-administered	Analyte	Population
264 ng/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/21563999	4 mg single, intravenous dose: 4 mg route of administration: Intravenous experiment type: SINGLE co-administered:		ZOLEDRONIC ACID plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
420 ng × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/21563999	4 mg single, intravenous dose: 4 mg route of administration: Intravenous experiment type: SINGLE co-administered:		ZOLEDRONIC ACID plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
39 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/21563999	4 mg single, intravenous dose: 4 mg route of administration: Intravenous experiment type: SINGLE co-administered:		ZOLEDRONIC ACID plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

Doses

Dose	Population	Adverse events
16 mg 1 times / 4 weeks multiple, intravenous Highest studied dose Dose: 16 mg, 1 times / 4 weeks Route: intravenous Route: multiple Dose: 16 mg, 1 times / 4 weeks Sources: https://pubmed.ncbi.nlm.nih.gov/12412821	unhealthy, 40-79 years n = 12 Health Status: unhealthy Condition: cancer Age Group: 40-79 years Sex: M+F Population Size: 12 Sources: https://pubmed.ncbi.nlm.nih.gov/12412821	Sources: https://pubmed.ncbi.nlm.nih.gov/12412821
16 mg single, intravenous Highest studied dose Dose: 16 mg Route: intravenous Route: single Dose: 16 mg Sources: https://pubmed.ncbi.nlm.nih.gov/11148571	unhealthy, 54 years (range: 34–73 years) n = 10 Health Status: unhealthy Condition: cancer Age Group: 54 years (range: 34–73 years) Sex: M+F Population Size: 10 Sources: https://pubmed.ncbi.nlm.nih.gov/11148571	Other AEs: Skeletal pain, Fever... Other AEs: Skeletal pain (30%) Fever (20%) Anorexia (20%) Diarrhea (20%) Constipation (10%) Nausea (20%) Myalgia (20%) Arthralgia (10%) Anemia (30%) Rigors (20%) Coughing (20%) Leg edema (10%) Urinary tract infection (10%) Fatigue (40%) Sources: https://pubmed.ncbi.nlm.nih.gov/11148571

AEs

AE	Significance	Dose	Population
Arthralgia	10%	16 mg single, intravenous Highest studied dose Dose: 16 mg Route: intravenous Route: single Dose: 16 mg Sources: https://pubmed.ncbi.nlm.nih.gov/11148571	unhealthy, 54 years (range: 34–73 years) n = 10 Health Status: unhealthy Condition: cancer Age Group: 54 years (range: 34–73 years) Sex: M+F Population Size: 10 Sources: https://pubmed.ncbi.nlm.nih.gov/11148571
Constipation	10%	16 mg single, intravenous Highest studied dose Dose: 16 mg Route: intravenous Route: single Dose: 16 mg Sources: https://pubmed.ncbi.nlm.nih.gov/11148571	unhealthy, 54 years (range: 34–73 years) n = 10 Health Status: unhealthy Condition: cancer Age Group: 54 years (range: 34–73 years) Sex: M+F Population Size: 10 Sources: https://pubmed.ncbi.nlm.nih.gov/11148571
Leg edema	10%	16 mg single, intravenous Highest studied dose Dose: 16 mg Route: intravenous Route: single Dose: 16 mg Sources: https://pubmed.ncbi.nlm.nih.gov/11148571	unhealthy, 54 years (range: 34–73 years) n = 10 Health Status: unhealthy Condition: cancer Age Group: 54 years (range: 34–73 years) Sex: M+F Population Size: 10 Sources: https://pubmed.ncbi.nlm.nih.gov/11148571
Urinary tract infection	10%	16 mg single, intravenous Highest studied dose Dose: 16 mg Route: intravenous Route: single Dose: 16 mg Sources: https://pubmed.ncbi.nlm.nih.gov/11148571	unhealthy, 54 years (range: 34–73 years) n = 10 Health Status: unhealthy Condition: cancer Age Group: 54 years (range: 34–73 years) Sex: M+F Population Size: 10 Sources: https://pubmed.ncbi.nlm.nih.gov/11148571
Anorexia	20%	16 mg single, intravenous Highest studied dose Dose: 16 mg Route: intravenous Route: single Dose: 16 mg Sources: https://pubmed.ncbi.nlm.nih.gov/11148571	unhealthy, 54 years (range: 34–73 years) n = 10 Health Status: unhealthy Condition: cancer Age Group: 54 years (range: 34–73 years) Sex: M+F Population Size: 10 Sources: https://pubmed.ncbi.nlm.nih.gov/11148571
Coughing	20%	16 mg single, intravenous Highest studied dose Dose: 16 mg Route: intravenous Route: single Dose: 16 mg Sources: https://pubmed.ncbi.nlm.nih.gov/11148571	unhealthy, 54 years (range: 34–73 years) n = 10 Health Status: unhealthy Condition: cancer Age Group: 54 years (range: 34–73 years) Sex: M+F Population Size: 10 Sources: https://pubmed.ncbi.nlm.nih.gov/11148571
Diarrhea	20%	16 mg single, intravenous Highest studied dose Dose: 16 mg Route: intravenous Route: single Dose: 16 mg Sources: https://pubmed.ncbi.nlm.nih.gov/11148571	unhealthy, 54 years (range: 34–73 years) n = 10 Health Status: unhealthy Condition: cancer Age Group: 54 years (range: 34–73 years) Sex: M+F Population Size: 10 Sources: https://pubmed.ncbi.nlm.nih.gov/11148571
Fever	20%	16 mg single, intravenous Highest studied dose Dose: 16 mg Route: intravenous Route: single Dose: 16 mg Sources: https://pubmed.ncbi.nlm.nih.gov/11148571	unhealthy, 54 years (range: 34–73 years) n = 10 Health Status: unhealthy Condition: cancer Age Group: 54 years (range: 34–73 years) Sex: M+F Population Size: 10 Sources: https://pubmed.ncbi.nlm.nih.gov/11148571
Myalgia	20%	16 mg single, intravenous Highest studied dose Dose: 16 mg Route: intravenous Route: single Dose: 16 mg Sources: https://pubmed.ncbi.nlm.nih.gov/11148571	unhealthy, 54 years (range: 34–73 years) n = 10 Health Status: unhealthy Condition: cancer Age Group: 54 years (range: 34–73 years) Sex: M+F Population Size: 10 Sources: https://pubmed.ncbi.nlm.nih.gov/11148571
Nausea	20%	16 mg single, intravenous Highest studied dose Dose: 16 mg Route: intravenous Route: single Dose: 16 mg Sources: https://pubmed.ncbi.nlm.nih.gov/11148571	unhealthy, 54 years (range: 34–73 years) n = 10 Health Status: unhealthy Condition: cancer Age Group: 54 years (range: 34–73 years) Sex: M+F Population Size: 10 Sources: https://pubmed.ncbi.nlm.nih.gov/11148571
Rigors	20%	16 mg single, intravenous Highest studied dose Dose: 16 mg Route: intravenous Route: single Dose: 16 mg Sources: https://pubmed.ncbi.nlm.nih.gov/11148571	unhealthy, 54 years (range: 34–73 years) n = 10 Health Status: unhealthy Condition: cancer Age Group: 54 years (range: 34–73 years) Sex: M+F Population Size: 10 Sources: https://pubmed.ncbi.nlm.nih.gov/11148571
Anemia	30%	16 mg single, intravenous Highest studied dose Dose: 16 mg Route: intravenous Route: single Dose: 16 mg Sources: https://pubmed.ncbi.nlm.nih.gov/11148571	unhealthy, 54 years (range: 34–73 years) n = 10 Health Status: unhealthy Condition: cancer Age Group: 54 years (range: 34–73 years) Sex: M+F Population Size: 10 Sources: https://pubmed.ncbi.nlm.nih.gov/11148571
Skeletal pain	30%	16 mg single, intravenous Highest studied dose Dose: 16 mg Route: intravenous Route: single Dose: 16 mg Sources: https://pubmed.ncbi.nlm.nih.gov/11148571	unhealthy, 54 years (range: 34–73 years) n = 10 Health Status: unhealthy Condition: cancer Age Group: 54 years (range: 34–73 years) Sex: M+F Population Size: 10 Sources: https://pubmed.ncbi.nlm.nih.gov/11148571
Fatigue	40%	16 mg single, intravenous Highest studied dose Dose: 16 mg Route: intravenous Route: single Dose: 16 mg Sources: https://pubmed.ncbi.nlm.nih.gov/11148571	unhealthy, 54 years (range: 34–73 years) n = 10 Health Status: unhealthy Condition: cancer Age Group: 54 years (range: 34–73 years) Sex: M+F Population Size: 10 Sources: https://pubmed.ncbi.nlm.nih.gov/11148571

Overview

CYP3A4	CYP2C9	CYP2D6	hERG

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP450 25	CYP 270

Drug as perpetrator

Target	Modality	Activity	Metabolite	Clinical evidence
CYP450 41	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/021817s000_PharmR_P1.pdf#page=50 Page: 50.0	no

Drug as victim

Target	Modality	Activity	Metabolite	Clinical evidence
CYP 270	substrate 3367 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5682380/	no

PubMed

Title	Date	PubMed
[Bisphosphonates in the treatment of breast carcinoma].	2001 Aug	11926150
Metastatic bone disease and tumour-induced hypercalcaemia: the role of bisphosphonates.	2001 Jun	12066026
FDA grants priority review for ZOMETA.	2001 Oct	12113096
The use of zoledronic acid, a novel, highly potent bisphosphonate, for the treatment of hypercalcemia of malignancy.	2002	12490736
The new bisphosphonate, Zometa (zoledronic acid), decreases skeletal complications in both osteolytic and osteoblastic lesions: a comparison to pamidronate.	2002	12442349
U.S. Food and Drug Administration drug approval summaries: imatinib mesylate, mesna tablets, and zoledronic acid.	2002	12401901
Actions of bisphosphonates in animal models of breast cancer.	2002	11879558
Development of bisphosphonates.	2002	11879557
Direct effects of bisphosphonates on breast cancer cells.	2002	11879555
FDA approves ZOMETA for treatment of cancer-related bone complications.	2002 Apr	12113230
Is there a dose response relationship for clodronate in the treatment of tumour induced hypercalcaemia?	2002 Apr 22	11953878
Bisphosphonates: biological response modifiers in breast cancer.	2002 Aug	12196279
Highly potent geminal bisphosphonates. From pamidronate disodium (Aredia) to zoledronic acid (Zometa).	2002 Aug 15	12166945
Advances in the biology and treatment of myeloma bone disease.	2002 Dec	12520479
The anti-tumour activity of bisphosphonates.	2002 Dec	12470981
Disease modifying and anti-nociceptive effects of the bisphosphonate, zoledronic acid in a model of bone cancer pain.	2002 Dec	12467993
Monosodium [1-hydroxy-2-(1H-imidazol-3-ium-4-yl)ethane-1,1-diyl]bis(phosphonate) tetrahydrate (monosodium isozoledronate).	2002 Dec	12466610
Pharmacological treatments for prostate cancer.	2002 Dec	12457434
The role of osteoclastic activity in prostate cancer skeletal metastases.	2002 Feb	12532187
Distinct mechanisms of bisphosphonate action between osteoblasts and breast cancer cells: identity of a potent new bisphosphonate analogue.	2002 Feb	12002344
Intravenous zoledronic acid in postmenopausal women with low bone mineral density.	2002 Feb 28	11870242
Bisphosphonates and osteoporosis.	2002 Feb 28	11870240
The effects of local administration of Zoledronate solution on the tooth movement and periodontal ligament.	2002 Jul	12411180
Osteoporosis: challenges and new opportunities for therapy.	2002 Jul	12197306
Bisphosphonates for cancer patients: why, how, and when?	2002 Jul	12136223
Novel therapeutic options for osteoporosis.	2002 Jul	12118183
Adaptive dose finding for phase I clinical trials of drugs used for chemotherapy of cancer.	2002 Jul 15	12111891
An investigation of bone resorption and Dictyostelium discoideum growth inhibition by bisphosphonate drugs.	2002 Jul 4	12086477
Bisphosphonates influence the proliferation and the maturation of normal human osteoblasts.	2002 Jun	12109626
Bisphosphonates and osteoporosis.	2002 Jun 27	12087149
Bisphosphonates inhibit stromelysin-1 (MMP-3), matrix metalloelastase (MMP-12), collagenase-3 (MMP-13) and enamelysin (MMP-20), but not urokinase-type plasminogen activator, and diminish invasion and migration of human malignant and endothelial cell lines.	2002 Mar	11984068
The effect of bone remodeling inhibition by zoledronic acid in an animal model of cartilage matrix damage.	2002 Mar	11869084
Treatment of malignant hypercalcaemia.	2002 May	11996631
The bisphosphonate zoledronic acid impairs Ras membrane [correction of impairs membrane] localisation and induces cytochrome c release in breast cancer cells.	2002 May 6	11986784
Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases.	2002 Nov	12412821
Severe increase in creatinine with hypocalcaemia in thalidomide-treated myeloma patients receiving zoledronic acid infusions.	2002 Nov	12406106
Pamidronate causes apoptosis of plasma cells in vivo in patients with multiple myeloma.	2002 Nov	12406088
Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats.	2002 Nov 15	12438248
Development and validation of a highly sensitive RIA for zoledronic acid, a new potent heterocyclic bisphosphonate, in human serum, plasma and urine.	2002 Nov 7	12408879
The use of bisphosphonates in patients with breast cancer.	2002 Nov-Dec	12514566
Bisphosphonate therapy in multiple myeloma: past, present, future.	2002 Nov-Dec	12460229
Zoledronic acid improves the mechanical properties of normal and healing bone.	2002 Nov-Dec	12446169
Zoledronic acid.	2002 Nov-Dec	12434471
Gateways to clinical trials.	2002 Oct	12500432
Zoledronic acid: new preparation. Just a me-too: no advance in hypercalcemia of malignancy.	2002 Oct	12378744
Intravenous zoledronic acid in postmenopausal women with low bone mineral density.	2002 Oct	12356057
Use of zoledronate to treat osteoblastic versus osteolytic lesions in a severe-combined-immunodeficient mouse model.	2002 Oct 1	12359769
A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma.	2002 Oct 2	12359855
Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid.	2002 Sep	12183663
[Bisphosphonates in bone metastases. Fewer fractures, less pain].	2002 Sep 26	12422697

Patents

Sample Use Guides

In Vivo Use Guide

The maximum recommended dose of Zometa in hypercalcemia of malignancy is 4 mg. The 4 mg dose must be given as a single-dose intravenous infusion over no less than 15 minutes.

Route of Administration: Intravenous

In Vitro Use Guide

For the transfection of the T24 human bladder cancer cells, pCMV6 empty vector (OriGene, Rockville, MD, USA) and pCMV6 TAp73 vector were transfected into cells using Lipofectamine™ 2000 (Invitrogen Life Technologies). After 6 h, the medium was refreshed and cultured for 48 h. Then the cells were treated with ZA (200 μM).

Substance Class	Chemical Created by `admin` on `Fri Dec 15 17:49:19 GMT 2023` Edited by `admin` on `Fri Dec 15 17:49:19 GMT 2023`
Record UNII	1K9U67HDID
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

ZOLEDRONIC ACID HEMIPENTAHYDRATE

Common Name

English

ZOLEDRONIC ACID HEMIPENTAHYDRATE [JAN]

Common Name

English

(1-HYDROXY-2-IMIDAZOL-1-YLETHYLIDENE)DIPHOSPHONIC ACID, HEMIPENTAHYDRATE

Common Name

English

Code System Code Type Description

EVMPD

SUB178554